论文部分内容阅读
目的观察慢性乙型肝炎患者围生期(perinatal)替比夫定(Telbivudine,LdT)抗病毒治疗对肌酸激酶(creatine kinase,CK)和乙肝病毒载量(HBV DNA)的影响。方法 12例围生期慢性乙型肝炎患者从乙肝标志物的角度分为HBsAg、HBeAg、HbcAb阳性(乙肝大三阳)8例,HBsAg、HBeAb、HbcAb阳性(乙肝小三阳)4例;从围生期的角度分为妊娠前2例、妊娠早期4例、妊娠中期2例、妊娠晚期4例。对LdT治疗前和分娩前CK和乙肝病毒载量(HBV DNA)进行监测,分析检测结果。结果 12例患者治疗后CK值未见异常;妊娠前和妊娠早期、妊娠中期的8例患者分娩前HBV DNA转阴性,妊娠晚期4例患者HBV DNA降至103~104。结论慢性乙型肝炎患者围生期使用LdT抗病毒治疗对CK无影响,而且降低HBV DNA效果确切。
Objective To investigate the effect of perinatal telbivudine (LdT) antiviral therapy on creatine kinase (CK) and hepatitis B virus (HBV) DNA in chronic hepatitis B patients. Methods Twelve patients with perinatal chronic hepatitis B were divided into four groups: HBsAg, HBeAg and HbcAb positive (HBeAg) in 8 patients with HBsAg, HBeAb and HbcAb positive (HBeAg) The perspective of birth is divided into 2 cases before pregnancy, 4 cases of early pregnancy, 2 cases of mid-pregnancy, 4 cases of late pregnancy. Before LdT treatment and before delivery and CK and hepatitis B virus load (HBV DNA) were monitored and the test results were analyzed. Results The CK values of 12 patients were normal after treatment. Before pregnancy and in the first trimester of pregnancy, 8 patients in the second trimester of pregnancy had negative HBV DNA before delivery and HBV DNA in the 4 patients in the third trimester dropped to 103-104. Conclusion Perinatal treatment of patients with chronic hepatitis B using LdT antiviral therapy has no effect on CK, and reduce HBV DNA exact effect.